TV scientists star in AstraZeneca's first ad campaign for asthma biologic Fasenra

TV doctors explain the ins and outs of esoinophilic asthma in the launch commercial for AstraZeneca's Fasenra. (AstraZeneca)

An ad within an ad is the theme of AstraZeneca’s first DTC campaign for Fasenra.

In the recently released TV commercial, scientists on TV talk about eosinophilic asthma while potential patients watch the “show” and react as they go about their daily lives. The TV scientists are wearing white lab coats with the AstraZeneca logo and answer interview questions in front of a room of other scientists and doctors. The campaign, targeted to reach people between the ages of 45 and 65, also includes print, digital, social media and in-office advertising.

RELATED: AstraZeneca goes to battle with GSK with nod for Nucala challenger Fasenra

“We wanted to bring to life the idea that scientists (which are portrayed by actors in the ad) are sharing important information to and for people with severe uncontrolled asthma while showing how those potential patients are reacting to receiving the new insight,” Mina Makar, executive director of respiratory biologics at AstraZeneca, said in an email interview.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download today and learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

Less than 2% of people with severe asthma know that eosinophils may be a potential cause, Maker said. An estimated 50% of people who have severe asthma may have elevated levels of eosinophils, which are white blood cells that are part of the immune system. A blood test can help determine if patients have eosinophilic asthma.

Fasenra was approved in November to treat eosinophilic asthma, a market that's led by GlaxoSmithKline's Nucala. GSK and Teva, which markets Cinqair, each had a head start on the market compared with Fasenra, but AZ is the first of the group to launch a DTC campaign.

“Today only 1 in 10 eligible severe asthma patients are currently on a biologic," Makar said, adding that "we believe this type of education is very important so patients better understand their disease."

RELATED: AstraZeneca's respiratory rivalry with GlaxoSmithKline takes a hit with Fasenra's phase 3 fail

AstraZeneca recently hit a snag in its quest to expand Fasenra into COPD and catch up to Nucala. In a phase 3 trial, the blockbuster hopeful couldn't top placebo at cutting down the rate of exacerbations, or episodes when symptoms suddenly worsen. AstraZeneca is awaiting results from another phase 3 study before it makes a decision about the drug’s fate in COPD.

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.